Qualities of an ideal beta-adrenoceptor antagonist and comparison of existing agents with a new cardioselective hydrophilic vasodilator beta-adrenoceptor antagonist, celiprolol.
Beta-adrenoceptor blockade is established therapy for cardiovascular conditions including hypertension and angina pectoris. The important qualities of a beta-adrenoceptor antagonist relate to cardioselectivity, hydrophilicity, peripheral vasodilation, ideal pharmacokinetics and maintenance of the quality of life. Celiprolol, with its known cardioselectivity, hydrophilicity and peripheral vasodilator capacity, measures well by several of these criteria; more data on pharmacokinetics are required. Further testing is indicated, particularly in relation to effects on epinephrine-induced hypokalemia, blood lipid profiles, clinical vasodilatory properties and effects on the quality of life, especially in geriatric patients.
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology; D000403:Airway Resistance / Q000187:drug effects; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D001262:Atenolol / Q000494:pharmacology; D017272:Celiprolol; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D011412:Propanolamines / Q000493:pharmacokinetics / Q000494:pharmacology; D012995:Solubility; D013566:Sympathomimetics; D014664:Vasodilation / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D008055:Lipids; D011412:Propanolamines; D013566:Sympathomimetics; D014665:Vasodilator Agents; D001262:Atenolol; D017272:Celiprolol